Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Biomarker profile in breast carcinomas presenting with bone metastasis.

Bohn OL, Nasir I, Brufsky A, Tseng GC, Bhargava R, MacManus K, Chivukula M.

Int J Clin Exp Pathol. 2009 Nov 10;3(2):139-46.

2.

Bone metastasis is strongly associated with estrogen receptor-positive/progesterone receptor-negative breast carcinomas.

Wei B, Wang J, Bourne P, Yang Q, Hicks D, Bu H, Tang P.

Hum Pathol. 2008 Dec;39(12):1809-15. doi: 10.1016/j.humpath.2008.05.010. Epub 2008 Aug 19.

PMID:
18715613
3.

Patterns of relapse and metastatic spread in HER2-overexpressing breast cancer according to estrogen receptor status.

Park YH, Lee S, Cho EY, Choi YL, Lee JE, Nam SJ, Yang JH, Ahn JS, Im YH.

Cancer Chemother Pharmacol. 2010 Aug;66(3):507-16. doi: 10.1007/s00280-009-1190-7. Epub 2009 Dec 3.

PMID:
19956951
4.

Organotropism and prognostic marker discordance in distant metastases of breast carcinoma: fact or fiction? A clinicopathologic analysis.

St Romain P, Madan R, Tawfik OW, Damjanov I, Fan F.

Hum Pathol. 2012 Mar;43(3):398-404. doi: 10.1016/j.humpath.2011.05.009. Epub 2011 Aug 12.

PMID:
21840040
5.

Apoptosis-, proliferation, immune function-, and drug resistance- related genes in ER positive, HER2 positive and triple negative breast cancer.

Kolacinska A, Chalubinska J, Zawlik I, Szymanska B, Borowska-Garganisz E, Nowik M, Fendler W, Kubiak R, Pawlowska Z, Morawiec Z, Szemraj J.

Neoplasma. 2012;59(4):424-32. doi: 10.4149/neo_2012_055.

PMID:
22489698
6.

Gene expression profiles of primary breast carcinomas from patients at high risk for local recurrence after breast-conserving therapy.

Kreike B, Halfwerk H, Kristel P, Glas A, Peterse H, Bartelink H, van de Vijver MJ.

Clin Cancer Res. 2006 Oct 1;12(19):5705-12.

7.

Expression and prognostic significance of metalloproteases and their inhibitors in luminal A and basal-like phenotypes of breast carcinoma.

González LO, Corte MD, Junquera S, González-Fernández R, del Casar JM, García C, Andicoechea A, Vázquez J, Pérez-Fernández R, Vizoso FJ.

Hum Pathol. 2009 Sep;40(9):1224-33. doi: 10.1016/j.humpath.2008.12.022. Epub 2009 May 12.

PMID:
19439346
8.

Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis.

Thorat MA, Marchio C, Morimiya A, Savage K, Nakshatri H, Reis-Filho JS, Badve S.

J Clin Pathol. 2008 Mar;61(3):327-32. Epub 2007 Nov 23.

PMID:
18037662
9.

Gene expression profiling of luminal B breast cancers reveals NHERF1 as a new marker of endocrine resistance.

Karn T, Ruckhäberle E, Hanker L, Müller V, Schmidt M, Solbach C, Gätje R, Gehrmann M, Holtrich U, Kaufmann M, Rody A.

Breast Cancer Res Treat. 2011 Nov;130(2):409-20. doi: 10.1007/s10549-010-1333-x. Epub 2011 Jan 4.

PMID:
21203899
10.

Poor-prognosis estrogen receptor-positive breast cancer identified by histopathologic subclassification.

Webster LR, Lee SF, Ringland C, Morey AL, Hanby AM, Morgan G, Byth K, Mote PA, Provan PJ, Ellis IO, Green AR, Lamoury G, Ravdin P, Clarke CL, Ward RL, Balleine RL, Hawkins NJ.

Clin Cancer Res. 2008 Oct 15;14(20):6625-33. doi: 10.1158/1078-0432.CCR-08-0701.

11.

Expression of KAI1/CD82 in distant metastases from estrogen receptor-negative breast cancer.

Christgen M, Christgen H, Heil C, Krech T, Länger F, Kreipe H, Lehmann U.

Cancer Sci. 2009 Sep;100(9):1767-71. doi: 10.1111/j.1349-7006.2009.01231.x. Epub 2009 May 27.

12.

CK19, CK20, EGFR and HER2 status of circulating tumor cells in patients with breast cancer.

Tunca B, Egeli U, Cecener G, Tezcan G, Gökgöz S, Tasdelen I, Bayram N, Tolunay S, Umut G, Demirdogen E, Erturk E, Ak S, Cetintas S, Evrensel T.

Tumori. 2012 Mar-Apr;98(2):243-51. doi: 10.1700/1088.11937.

PMID:
22677992
13.

Prognostic relevance of carcinoembryonic antigen and estrogen receptor status in breast cancer patients.

Esteban JM, Felder B, Ahn C, Simpson JF, Battifora H, Shively JE.

Cancer. 1994 Sep 1;74(5):1575-83.

14.

A novel mouse model of human breast cancer stem-like cells with high CD44+CD24-/lower phenotype metastasis to human bone.

Ling LJ, Wang S, Liu XA, Shen EC, Ding Q, Lu C, Xu J, Cao QH, Zhu HQ, Wang F.

Chin Med J (Engl). 2008 Oct 20;121(20):1980-6.

PMID:
19080260
15.

Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis.

D'Andrea MR, Limiti MR, Bari M, Zambenedetti P, Montagutti A, Ricci F, Pappagallo GL, Sartori D, Vinante O, Mingazzini PL.

Breast Cancer Res Treat. 2007 Mar;101(3):279-84. Epub 2006 Jul 12.

PMID:
16835704
16.

Discordant expression of hormone receptors and HER2 in breast cancer. A retrospective comparison of primary tumors with paired metachronous recurrences or metastases.

Arapantoni-Dadioti P, Valavanis C, Gavressea T, Tzaida O, Trihia H, Lekka I.

J BUON. 2012 Apr-Jun;17(2):277-83.

PMID:
22740206
17.

Biologic role of activated leukocyte cell adhesion molecule overexpression in breast cancer cell lines and clinical tumor tissue.

Hein S, Müller V, Köhler N, Wikman H, Krenkel S, Streichert T, Schweizer M, Riethdorf S, Assmann V, Ihnen M, Beck K, Issa R, Jänicke F, Pantel K, Milde-Langosch K.

Breast Cancer Res Treat. 2011 Sep;129(2):347-60. doi: 10.1007/s10549-010-1219-y. Epub 2010 Oct 23.

PMID:
20972617
18.

Implications of different CA 15-3 levels according to breast cancer subtype at initial diagnosis of recurrent or metastatic breast cancer.

Park S, Ahn HK, Park LC, Hwang DW, Ji JH, Maeng CH, Cho SH, Lee JY, Park KT, Ahn JS, Park YH, Im YH.

Oncology. 2012;82(3):180-7. doi: 10.1159/000336081. Epub 2012 Mar 16.

PMID:
22433564
19.

Increased expression of a set of genes enriched in oxygen binding function discloses a predisposition of breast cancer bone metastases to generate metastasis spread in multiple organs.

Capulli M, Angelucci A, Driouch K, Garcia T, Clement-Lacroix P, Martella F, Ventura L, Bologna M, Flamini S, Moreschini O, Lidereau R, Ricevuto E, Muraca M, Teti A, Rucci N.

J Bone Miner Res. 2012 Nov;27(11):2387-98. doi: 10.1002/jbmr.1686.

20.

Primary tumour expression of the cysteine cathepsin inhibitor Stefin A inhibits distant metastasis in breast cancer.

Parker BS, Ciocca DR, Bidwell BN, Gago FE, Fanelli MA, George J, Slavin JL, Möller A, Steel R, Pouliot N, Eckhardt B, Henderson MA, Anderson RL.

J Pathol. 2008 Feb;214(3):337-46.

PMID:
17985332

Supplemental Content

Support Center